144 related articles for article (PubMed ID: 33711411)
1. Ablative radiotherapy for ultracentral lung cancers: Dosimetric, geometric, and volumetric predictors of outcomes and toxicity.
Breen WG; Jeans EB; Gergelis KR; Garces YI; Park SS; Merrell KW; Peikert TD; Mansfield AS; Wigle DA; Harmsen WS; Ellerbusch DC; Olivier KR; John Lucido J; Owen D
Radiother Oncol; 2021 May; 158():246-252. PubMed ID: 33711411
[TBL] [Abstract][Full Text] [Related]
2. Assessment of Monte Carlo algorithm for compliance with RTOG 0915 dosimetric criteria in peripheral lung cancer patients treated with stereotactic body radiotherapy.
Pokhrel D; Sood S; Badkul R; Jiang H; McClinton C; Lominska C; Kumar P; Wang F
J Appl Clin Med Phys; 2016 May; 17(3):277-293. PubMed ID: 27167284
[TBL] [Abstract][Full Text] [Related]
3. Tumor Control and Toxicity after SBRT for Ultracentral, Central, and Paramediastinal Lung Tumors.
Nguyen KNB; Hause DJ; Novak J; Monjazeb AM; Daly ME
Pract Radiat Oncol; 2019 Mar; 9(2):e196-e202. PubMed ID: 30496842
[TBL] [Abstract][Full Text] [Related]
4. Stereotactic ablative radiotherapy of 60 Gy in eight fractions is safe for ultracentral non-small cell lung cancer.
Yang D; Cui J; Zhao J; You J; Yu R; Yu H; Jiang L; Li D; Xu B; Shi A
Thorac Cancer; 2020 Mar; 11(3):754-761. PubMed ID: 32012484
[TBL] [Abstract][Full Text] [Related]
5. Local control and toxicity in a large cohort of central lung tumors treated with stereotactic body radiation therapy.
Modh A; Rimner A; Williams E; Foster A; Shah M; Shi W; Zhang Z; Gelblum DY; Rosenzweig KE; Yorke ED; Jackson A; Wu AJ
Int J Radiat Oncol Biol Phys; 2014 Dec; 90(5):1168-76. PubMed ID: 25303891
[TBL] [Abstract][Full Text] [Related]
6. Stereotactic ablative radiotherapy for ultra-central lung tumors: prioritize target coverage or organs at risk?
Murrell DH; Laba JM; Erickson A; Millman B; Palma DA; Louie AV
Radiat Oncol; 2018 Apr; 13(1):57. PubMed ID: 29606150
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of Hypofractionated High-Dose Radiotherapy in Poor-Risk Patients with "Ultracentral" Non-Small Cell Lung Cancer.
Tekatli H; Haasbeek N; Dahele M; De Haan P; Verbakel W; Bongers E; Hashemi S; Nossent E; Spoelstra F; de Langen AJ; Slotman B; Senan S
J Thorac Oncol; 2016 Jul; 11(7):1081-9. PubMed ID: 27013408
[TBL] [Abstract][Full Text] [Related]
8. SUNSET: Stereotactic Radiation for Ultracentral Non-Small-Cell Lung Cancer-A Safety and Efficacy Trial.
Giuliani M; Mathew AS; Bahig H; Bratman SV; Filion E; Glick D; Louie AV; Raman S; Swaminath A; Warner A; Yau V; Palma D
Clin Lung Cancer; 2018 Jul; 19(4):e529-e532. PubMed ID: 29759332
[TBL] [Abstract][Full Text] [Related]
9. The significance of PTV dose coverage on cancer control outcomes in early stage non-small cell lung cancer patients treated with highly ablative stereotactic body radiation therapy.
Shaverdian N; Tenn S; Veruttipong D; Wang J; Hegde J; Lee C; Cao M; Agazaryan N; Steinberg M; Kupelian P; Lee P
Br J Radiol; 2016; 89(1059):20150963. PubMed ID: 26764282
[TBL] [Abstract][Full Text] [Related]
10. Dosimetric definitions of total lung volumes in calculating parameters predictive for radiation-induced pneumonitis.
Kabolizadeh P; Kalash R; Huq MS; Greenberger JS; Heron DE; Beriwal S
Am J Clin Oncol; 2015 Aug; 38(4):401-4. PubMed ID: 24064747
[TBL] [Abstract][Full Text] [Related]
11. Magnetic resonance guided adaptive stereotactic body radiotherapy for lung tumors in ultracentral location: the MAGELLAN trial (ARO 2021-3).
Regnery S; Ristau J; Weykamp F; Hoegen P; Sprengel SD; Paul KM; Buchele C; Klüter S; Rippke C; Renkamp CK; Pohl M; Meis J; Welzel T; Adeberg S; Koerber SA; Debus J; Hörner-Rieber J
Radiat Oncol; 2022 May; 17(1):102. PubMed ID: 35614486
[TBL] [Abstract][Full Text] [Related]
12. Potential for reduced toxicity and dose escalation in the treatment of inoperable non-small-cell lung cancer: a comparison of intensity-modulated radiation therapy (IMRT), 3D conformal radiation, and elective nodal irradiation.
Grills IS; Yan D; Martinez AA; Vicini FA; Wong JW; Kestin LL
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):875-90. PubMed ID: 14529795
[TBL] [Abstract][Full Text] [Related]
13. Non-coplanar VMAT combined with non-uniform dose prescription markedly reduces lung dose in breath-hold lung SBRT.
Fleckenstein J; Boda-Heggemann J; Siebenlist K; Gudzheva T; Prakofyeva N; Lohr F; Wenz F; Simeonova-Chergou A
Strahlenther Onkol; 2018 Sep; 194(9):815-823. PubMed ID: 29802434
[TBL] [Abstract][Full Text] [Related]
14. Improving geometric sparing and therapeutic effectiveness of lung SBRT for central and ultra-central tumors.
Fakir H; Randhawa GK; Millman B; Laba J
Med Dosim; 2021 Winter; 46(4):398-403. PubMed ID: 34172369
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcomes in patients with central and ultracentral non-small cell lung cancer treated with stereotactic body radiotherapy: single-institution experience.
Song X; Zhao L; Jiang N; Ding N; Zong D; Zhang N; Wang D; Wen J; He X; Kong C; Zhu X
Curr Probl Cancer; 2023 Jun; 47(3):100956. PubMed ID: 36966677
[TBL] [Abstract][Full Text] [Related]
16. On the pitfalls of PTV in lung SBRT using type-B dose engine: an analysis of PTV and worst case scenario concepts for treatment plan optimization.
Leung RWK; Chan MKH; Chiang CL; Wong M; Blanck O
Radiat Oncol; 2020 May; 15(1):130. PubMed ID: 32471457
[TBL] [Abstract][Full Text] [Related]
17. Dose-response relationship with clinical outcome for lung stereotactic body radiotherapy (SBRT) delivered via online image guidance.
Kestin L; Grills I; Guckenberger M; Belderbos J; Hope AJ; Werner-Wasik M; Sonke JJ; Bissonnette JP; Xiao Y; Yan D;
Radiother Oncol; 2014 Mar; 110(3):499-504. PubMed ID: 24630539
[TBL] [Abstract][Full Text] [Related]
18. Ultracentral Tumors Treated With Stereotactic Body Radiotherapy: Single-Institution Experience.
Raman S; Yau V; Pineda S; Le LW; Lau A; Bezjak A; Cho BCJ; Sun A; Hope AJ; Giuliani M
Clin Lung Cancer; 2018 Sep; 19(5):e803-e810. PubMed ID: 30007498
[TBL] [Abstract][Full Text] [Related]
19. Accelerated hypofractionated magnetic resonance-guided adaptive radiotherapy for oligoprogressive non-small cell lung cancer.
La Rosa A; Mittauer KE; Chuong MD; Hall MD; Kutuk T; Bassiri N; McCulloch J; Alvarez D; Herrera R; Gutierrez AN; Tolakanahalli R; Mehta MP; Kotecha R
Med Dosim; 2023 Winter; 48(4):238-244. PubMed ID: 37330328
[TBL] [Abstract][Full Text] [Related]
20. Dosimetric comparison of stereotactic body radiotherapy using 4D CT and multiphase CT images for treatment planning of lung cancer: evaluation of the impact on daily dose coverage.
Wang L; Hayes S; Paskalev K; Jin L; Buyyounouski MK; Ma CC; Feigenberg S
Radiother Oncol; 2009 Jun; 91(3):314-24. PubMed ID: 19111362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
